Table 2 MCDA criteria, Test Anova, SLAM, AHP weights and the results of sensitivity analysis
Test Anova | SLAM | AHP weights | VIP min | VIP max | Max Regret | |
|---|---|---|---|---|---|---|
Indication uniquenes | 0.8529 | 10 | 2.31% | 0.12 | 0.5 | 0.87 |
Disease rarity | 0.4815 | 8 | 3.34% | 0.3 | 0.66 | 0.69 |
Disease severity | 0.4837 | 9 | 3.38% | 0.23 | 0.5 | 0.76 |
Adv.tech. | 0.7574 | 12 | 0.42% | 0 | 0.05 | 1.00 |
Manufacturing technology | 0.2169 | 13 | 0.23% | 0 | 0.02 | 1.00 |
Therapeutic alternative | 0.3666 | 4 | 8.56% | 0.5 | 0.67 | 0.5 |
Sci. evid. Clin.eff | 0.2546 | 1 | 14.76% | 0.98 | 1.00 | 0.00 |
Benefits from use of medicine (safety aspects) | 0.0071* | 3 | 12.68% | 0.5 | 0.81 | 0.5 |
Cost effectiveness analysis | 0.0747 | 5 | 9.86% | 0.48 | 1.00 | 0.52 |
Budget impact analysis | 0.646 | 6 | 10.26% | 0.44 | 0.58 | 0.56 |
Therapy cost | 0.2937 | 2 | 17.60% | 0.5 | 0.82 | 0.5 |
HTA recommendations issued elsewhere | 0.0691 | 7 | 11.88% | 0.48 | 0.83 | 0.51 |
Rationalization analysis | 0.0176* | 11 | 4.73% | 0.13 | 0.5 | 0.87 |